RIGEL PHARMACEUTICALS INC RIGL

Latest FY: 2025 Healthcare Biotechnology
Market Price $42.36
Market Cap $755.81M
P/E Ratio 2.17
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑64.1% YoY
$294.28M
3-Yr CAGR: 34.8%
Net Income ↑1,999.1% YoY
$367.02M
Net Margin: 124.7%
Free Cash Flow ↑140.7% YoY
$75.66M
FCF Yield: 10.01%
EPS (Diluted) ↑1,867.7% YoY
$19.48
Basic: $20.40
Return on Equity Efficiency
93.8%
ROA: 1,672.7%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (RIGL)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (-78.0%) is identical to Gross Profit YoY (-78.0%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $20.4M $18.3M $-69.2M $-75.9M $-76.7M
FY 2017 $4.5M -78.0% $4.0M $-78.0M -12.7% $-77.6M $-77.7M -1.3%
FY 2018 $44.5M +892.6% $44.2M $-70.5M +9.6% $-58.8M $-59.9M +22.9%
FY 2019 $59.3M +33.2% $58.4M $-66.9M +5.1% $-41.5M $-43.0M +28.3%
FY 2020 $108.6M +83.2% $107.3M $-29.7M +55.5% $-52.2M $-53.4M -24.4%
FY 2021 $149.2M +37.4% $144.4M $-17.9M +39.8% $-0.11 $5.9M $5.3M +109.8%
FY 2022 $120.2M -19.4% $116.5M $-58.6M -227.0% $-0.34 -209.1% $-73.8M $-74.2M -1,513.2%
FY 2023 $116.9M -2.8% $109.8M $-25.1M +57.2% $-0.14 +58.8% $-5.7M $-5.7M +92.3%
FY 2024 $179.3M +53.4% $160.6M $17.5M +169.7% $0.99 +807.1% $31.5M $31.4M +647.4%
FY 2025 $294.3M +64.1% $274.7M $367.0M +1,999.1% $19.48 +1,867.7% $75.7M $75.7M +140.7%
$

Valuation

Market Price $42.36
Market Cap $755.81M
Enterprise Value $767.73M
P/E Ratio 2.17
P/B Ratio 2.00
FCF Yield 10.01%
Dividend Yield N/A
Shares Outstanding 18,502,100
%

Profitability & Margins

Gross Margin 93.33%
Operating Margin 42.63%
Net Margin 124.72%
Return on Equity (ROE) 93.75%
Return on Assets (ROA) 1,672.70%
Asset Turnover 13.41x
Revenue 3-Yr CAGR 34.76%
🛡️

Financial Health & Liquidity

Current Ratio 0.22
Cash Ratio 0.41
Debt / Equity 0.134
Debt / Assets 2.393
Cash & Equivalents $40.58M
Total Debt $52.50M
Book Value / Share $21.16
💧

Cash Flow Efficiency

Operating Cash Flow $75.66M
Capital Expenditures (CapEx) N/A
Free Cash Flow $75.66M
OCF / Revenue 25.71%
FCF / Revenue 25.71%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $19.48
EPS (Basic) $20.40
Dividends / Share N/A
Book Value / Share $21.16
EPS YoY Growth 1,867.68%
🏛️

Balance Sheet (FY 2025)

Total Assets $21.94M
Total Liabilities $99.24M
Stockholders' Equity $391.48M
Current Assets $21.94M
Current Liabilities $99.24M